Proteome Sciences (LON:PRM) Stock Price Down 18.5% – Should You Sell?

Shares of Proteome Sciences plc (LON:PRM) were down 18.5% during mid-day trading on Thursday . The stock traded as low as GBX 2.89 ($0.04) and last traded at GBX 2.89 ($0.04). Approximately 1,014,536 shares changed hands during trading, an increase of 367% from the average daily volume of 217,283 shares. The stock had previously closed at GBX 3.55 ($0.05).

Proteome Sciences Trading Up 12.3 %

The company has a current ratio of 0.20, a quick ratio of 0.37 and a debt-to-equity ratio of -258.66. The firm has a 50-day moving average price of GBX 4.05 and a 200-day moving average price of GBX 3.46. The company has a market capitalization of £9.98 million, a price-to-earnings ratio of -2.45 and a beta of 0.07.

Proteome Sciences (LON:PRM) last issued its quarterly earnings results on Thursday, April 10th. The company reported GBX (1.15) (($0.02)) EPS for the quarter. Proteome Sciences had a negative return on equity of 0.01% and a negative net margin of 0.04%.

Proteome Sciences Company Profile

Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in plasma and other samples where quantitative accuracy is a factor; SysQuant, provides an analysis of protein activity across regulatory and signaling pathways; and TMTcalibrator, analyzes where diseased or treated tissue can be analyzed in parallel with peripheral fluids.